AstraZeneca has signed a deal with yet another Indian firm, this time with Intas Pharmaceuticals, to sell branded generics.
Following hard on the heels of pacts with Aurobindo Pharma and Torrent Pharmaceuticals, the Intas link-up will see the Ahmedabad-based firm provide the Anglo-Swedish drugmaker with injectable and oral cancer drugs. AstraZeneca will source products from Intas’s manufacturing site at Matoda and sell them as branded generics in emerging markets in Latin America, Africa and the Commonwealth of Independent States countries.
The specific financial terms of the agreement were not disclosed, although Jayesh Shah, chief financial officer of Intas Pharma, was quoted in the Business Standard newspaper as saying “we have a received a couple of million dollars upfront from Astrazeneca”, which is 20% of the total deal value.
AstraZeneca spokeswoman Abigail Baron told PharmaTimes World News that “as part of our emerging markets strategy day back in March, we outlined our plans to broaden our product portfolio to include carefully chosen branded generics”. She added that the company expects the latter to account for “about 10-15% of our business in emerging markets in 2014”.
